Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of amlitelimab in moderate-to-severe atopic dermatitis
jRCT2061230089Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: vIGA-AD 0/1 with ≥2-point reduction at Week 24 (EU/EU reference/Japan), EASI-75 at Week 24 (EU/EU reference/Japan) and 1 more. Started Jan 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061230089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230089.